{"count": 1, "results": [{"_id": "33757860", "pmid": 33757860, "title": "The safety and efficacy of metformin in fragile X syndrome: An open-label study.", "journal": "Prog Neuropsychopharmacol Biol Psychiatry", "authors": ["Proteau-Lemieux M", "Lacroix A", "Galarneau L", "Corbin F", "Lepage JF", "Çaku A"], "date": "2021-08-30T00:00:00Z", "doi": "10.1016/j.pnpbp.2021.110307", "meta_date_publication": "2021 Aug 30", "meta_volume": "110", "meta_issue": "", "meta_pages": "110307", "score": 50256.297, "text_hl": "Preclinical studies have shown that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ downregulates the insulin/@GENE_IGF1 @GENE_16000 @@@IGF-1@@@ signaling pathway, corrects @<m>DISEASE_Keratitis_Dendritic</m> @DISEASE_MESH:D007635 @@@dendritic@@@ defects, and improves repetitive behavior in @GENE_FMR1 @GENE_14265 @@@Fmr1@@@ knockout @SPECIES_10090 @@@mice@@@. ", "citations": {"NLM": "Proteau-Lemieux M, Lacroix A, Galarneau L, Corbin F, Lepage JF, Çaku A. The safety and efficacy of metformin in fragile X syndrome: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110():110307. PMID: 33757860", "BibTeX": "@article{33757860, title={The safety and efficacy of metformin in fragile X syndrome: An open-label study.}, author={Proteau-Lemieux M and Lacroix A and Galarneau L and Corbin F and Lepage JF and Çaku A}, journal={Prog Neuropsychopharmacol Biol Psychiatry}, volume={110}, pages={110307}}"}}]}